High prevalence of HIV-1 transmitted drug resistance and factors associated with time to virological failure and viral suppression in Taiwan.
Journal
The Journal of antimicrobial chemotherapy
ISSN: 1460-2091
Titre abrégé: J Antimicrob Chemother
Pays: England
ID NLM: 7513617
Informations de publication
Date de publication:
24 12 2021
24 12 2021
Historique:
received:
07
06
2021
accepted:
06
09
2021
pubmed:
15
10
2021
medline:
4
3
2022
entrez:
14
10
2021
Statut:
ppublish
Résumé
Integrase strand transfer inhibitor (InSTI)-based regimens have become the major first-line treatment for HIV-1-infected patients in Taiwan. Transmitted drug resistance (TDR) and several clinical characteristics are associated with time to virological failure or viral suppression; however, these have not been investigated in Taiwan. To determine the impact of several factors on treatment outcomes in HIV-1-infected patients in Taiwan. The cohort included 164 HIV-1 treatment-naive patients in Taiwan from 2018 to 2020. Blood specimens were collected to determine the genotypic drug resistance using the Stanford University HIV drug resistance database. Cox proportional hazards models were used to identify factors associated with time to virological failure or viral suppression. The prevalence of TDR in Taiwan was 27.4% and an increasing trend was seen from 2018 to 2020. TDR mutations related to NNRTIs were the most prevalent (21%) while TDR to InSTIs remained at a relatively low level (1.3%). A baseline HIV-1 viral load of ≥100 000 copies/mL was associated with a shorter time to virological failure [multivariate hazard ratio (mHR) 7.84; P = 0.018] and longer time to viral suppression (mHR 0.46; P < 0.001). Time to viral suppression was shorter in patients receiving InSTI-based regimens (mHR 2.18; P = 0.006). Different InSTI-based regimens as initial treatment did not affect the treatment outcomes. This study found an increasing trend of HIV-1 TDR prevalence from 2018 to 2020 in Taiwan. Baseline HIV-1 viral load and receiving InSTI-based regimens are important factors associated with time to virological failure or viral suppression.
Sections du résumé
BACKGROUND
Integrase strand transfer inhibitor (InSTI)-based regimens have become the major first-line treatment for HIV-1-infected patients in Taiwan. Transmitted drug resistance (TDR) and several clinical characteristics are associated with time to virological failure or viral suppression; however, these have not been investigated in Taiwan.
OBJECTIVES
To determine the impact of several factors on treatment outcomes in HIV-1-infected patients in Taiwan.
METHODS
The cohort included 164 HIV-1 treatment-naive patients in Taiwan from 2018 to 2020. Blood specimens were collected to determine the genotypic drug resistance using the Stanford University HIV drug resistance database. Cox proportional hazards models were used to identify factors associated with time to virological failure or viral suppression.
RESULTS
The prevalence of TDR in Taiwan was 27.4% and an increasing trend was seen from 2018 to 2020. TDR mutations related to NNRTIs were the most prevalent (21%) while TDR to InSTIs remained at a relatively low level (1.3%). A baseline HIV-1 viral load of ≥100 000 copies/mL was associated with a shorter time to virological failure [multivariate hazard ratio (mHR) 7.84; P = 0.018] and longer time to viral suppression (mHR 0.46; P < 0.001). Time to viral suppression was shorter in patients receiving InSTI-based regimens (mHR 2.18; P = 0.006). Different InSTI-based regimens as initial treatment did not affect the treatment outcomes.
CONCLUSIONS
This study found an increasing trend of HIV-1 TDR prevalence from 2018 to 2020 in Taiwan. Baseline HIV-1 viral load and receiving InSTI-based regimens are important factors associated with time to virological failure or viral suppression.
Identifiants
pubmed: 34648632
pii: 6397013
doi: 10.1093/jac/dkab361
pmc: PMC8851067
doi:
Substances chimiques
HIV Integrase Inhibitors
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
185-195Informations de copyright
© The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please email: journals.permissions@oup.com.
Références
Heliyon. 2019 Sep 11;5(9):e02411
pubmed: 31535044
N Engl J Med. 2015 Aug 27;373(9):795-807
pubmed: 26192873
PLoS One. 2014 Dec 11;9(12):e114441
pubmed: 25502811
Epidemiol Infect. 2018 Feb;146(3):339-344
pubmed: 29345606
J Acquir Immune Defic Syndr. 2008 Jul 1;48(3):324-33
pubmed: 18545152
J Microbiol Immunol Infect. 2016 Aug;49(4):487-93
pubmed: 25315212
BMC Infect Dis. 2019 Aug 23;19(1):741
pubmed: 31443633
BMC Infect Dis. 2019 Apr 8;19(1):313
pubmed: 30961560
J Antimicrob Chemother. 2021 Aug 12;76(9):2407-2414
pubmed: 33993252
AIDS Res Hum Retroviruses. 2016 Feb;32(2):148-54
pubmed: 26670218
BMC Infect Dis. 2017 May 3;17(1):326
pubmed: 28468608
J Infect Dis. 2009 Nov 15;200(10):1503-8
pubmed: 19835478
J Acquir Immune Defic Syndr. 2001 Dec 1;28(4):313-9
pubmed: 11707666
Clin Infect Dis. 2012 Jan 1;54(1):131-40
pubmed: 22057700
J Antimicrob Chemother. 2021 Feb 11;76(3):722-728
pubmed: 33331635
Antimicrob Agents Chemother. 2015 Feb;59(2):960-71
pubmed: 25421485
J Virol. 2008 Nov;82(21):10747-55
pubmed: 18715933
Antimicrob Agents Chemother. 2000 Sep;44(9):2475-84
pubmed: 10952598
HIV Med. 2017 Mar;18(3):204-213
pubmed: 27476929
J Infect Dis. 2003 Nov 15;188(10):1421-5
pubmed: 14624366
Lancet Infect Dis. 2011 May;11(5):363-71
pubmed: 21354861
Oncotarget. 2018 May 18;9(38):24927-24935
pubmed: 29861843
N Engl J Med. 2016 Sep 1;375(9):830-9
pubmed: 27424812
J Antimicrob Chemother. 2014 Jan;69(1):12-20
pubmed: 23934770
Sci Rep. 2016 Oct 25;6:35779
pubmed: 27779200
J Acquir Immune Defic Syndr. 2005 Mar 1;38(3):289-95
pubmed: 15735446
Arch Intern Med. 2002 Oct 14;162(18):2125-32
pubmed: 12374521
Int J Antimicrob Agents. 2021 May;57(5):106343
pubmed: 33852932
AIDS. 2007 Oct 18;21(16):2223-9
pubmed: 18090050
JAMA. 2020 Oct 27;324(16):1651-1669
pubmed: 33052386
Lancet. 2012 Jun 30;379(9835):2439-2448
pubmed: 22748591
Clin Infect Dis. 2013 Apr;56(8):1174-82
pubmed: 23315317
Lancet. 2009 Sep 5;374(9692):796-806
pubmed: 19647866
HIV Med. 2008 May;9(5):285-93
pubmed: 18400075
AIDS Patient Care STDS. 2015 Jul;29(7):370-8
pubmed: 26061798
Clin Infect Dis. 2014 Feb;58(3):423-31
pubmed: 24145878
J Infect Dis. 2016 Aug 1;214(3):399-402
pubmed: 27130429
J Infect Dis. 2017 Mar 15;215(6):920-927
pubmed: 28453836
J Antimicrob Chemother. 2017 Jan;72(1):205-209
pubmed: 27624569
J Antimicrob Chemother. 2020 Jan 1;75(1):170-182
pubmed: 31617907
AIDS Rev. 2015 Jul-Sep;17(3):171-85
pubmed: 26450805
Sci Rep. 2016 Sep 06;6:32947
pubmed: 27597312
J Antimicrob Chemother. 2012 May;67(5):1254-60
pubmed: 22302562
Lancet. 2002 Jul 13;360(9327):119-29
pubmed: 12126821
J Antimicrob Chemother. 2017 Dec 1;72(12):3425-3434
pubmed: 28961719
Antivir Ther. 2009;14(1):103-9
pubmed: 19320243
J Acquir Immune Defic Syndr. 2010 Sep;55(1):95-101
pubmed: 20585262
AIDS Res Hum Retroviruses. 2018 Aug;34(8):672-679
pubmed: 29732898
J Antimicrob Chemother. 2016 Jan;71(1):226-34
pubmed: 26404079
J Acquir Immune Defic Syndr. 2012 Nov 1;61(3):265-9
pubmed: 22895438
AIDS. 2014 Nov 28;28(18):2751-62
pubmed: 25493601
J Virus Erad. 2019 Nov 4;5(4):204-211
pubmed: 31754443
Front Pharmacol. 2021 Jul 21;12:603068
pubmed: 34366835
AIDS Care. 2016 Nov;28(11):1355-64
pubmed: 27297952
Medicine (Baltimore). 2018 Oct;97(43):e13016
pubmed: 30412140
Clin Infect Dis. 2021 Oct 5;73(7):e2134-e2141
pubmed: 33095848
N Engl J Med. 2013 Nov 7;369(19):1807-18
pubmed: 24195548
HIV Med. 2013 May;14(5):284-92
pubmed: 23171153
Nucleic Acids Res. 2003 Jan 1;31(1):298-303
pubmed: 12520007
J Antimicrob Chemother. 2010 Jul;65(7):1477-85
pubmed: 20462946
AIDS Behav. 2016 Aug;20(8):1603-8
pubmed: 26809193
Clin Infect Dis. 2005 Feb 1;40(3):468-74
pubmed: 15668873